share_log

Canopy Growth | 8-K: Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

SEC ·  Nov 8, 2024 07:15

Summary by Moomoo AI

Canopy Growth reported Q2 FY2025 net revenue of $63 million, down 9% year-over-year, while gross margin improved 100 basis points to 35%. The decline was partially offset by 16% growth in Canadian medical cannabis and 12% growth in international markets. Storz & Bickel vaporizer business saw strong 32% revenue growth to $16 million.The company reduced its adjusted EBITDA loss by 54% to $5.5 million, driven by cost savings initiatives. Free cash flow improved 16% to negative $56.4 million. The balance sheet strengthened with cash and short-term investments increasing to $231 million from $195 million in the previous quarter.Looking ahead, management expects accelerated momentum in the second half, supported by the re-introduction of Wana edibles and new product launches. The company remains on track to achieve positive adjusted EBITDA in coming quarters through topline growth and continued cost discipline.
Canopy Growth reported Q2 FY2025 net revenue of $63 million, down 9% year-over-year, while gross margin improved 100 basis points to 35%. The decline was partially offset by 16% growth in Canadian medical cannabis and 12% growth in international markets. Storz & Bickel vaporizer business saw strong 32% revenue growth to $16 million.The company reduced its adjusted EBITDA loss by 54% to $5.5 million, driven by cost savings initiatives. Free cash flow improved 16% to negative $56.4 million. The balance sheet strengthened with cash and short-term investments increasing to $231 million from $195 million in the previous quarter.Looking ahead, management expects accelerated momentum in the second half, supported by the re-introduction of Wana edibles and new product launches. The company remains on track to achieve positive adjusted EBITDA in coming quarters through topline growth and continued cost discipline.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more